Vaxil Bio Ltd (VXLLF)

[breezy1]

Just read the news

[everything]

No love for this Vavil Biol Ltd?
Saw it mentioned here and there is about it, maybe early days or something? Just seen it moving up and wondering about it.

[breezy1]

https://finance.yahoo.com/news/vaxil-provides-business-corvax-experiments-125500704.html

[WebSlinger]

Vaxil Enters Into a Cooperative Research and Development Agreement With U.S. Army Medical Research Institute of Infectious Diseases ("USAMRIID")

VAXIL BIO LTD. ("Vaxil" or the "Company") (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce that on October 26, 2020, it has entered into a cooperative research and development agreement (CRADA) with USAMRIID under which USAMRIID will test CorVax(TM) for its ability to specifically prevent COVID-19 in mice.

Vaxil recently reported that its CorVax(TM) successfully generated an immune response in the experiment carried out at the Allergy and Clinical Immunology Unit at the Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Sourasky Medical Center in Israel by Dr. David Hagin. As a result, the Company is progressing to the next study to test whether this immune response is specific enough to COVID-19 to provide protection against the virus in a mouse model.

As scientists and companies race to find vaccines to prevent COVID-19 infection, some platforms are focused on mRNA, others on viral vectors, viruses and various subunits. Vaxil is, to the best of the Company's knowledge, the only company working with signal peptides, which offer unique advantages of efficacy in stimulating a broad immune response while achieving a suitable safety profile. Vaxil's signal peptide platform has proven safety in a phase 1/2a study in oncology.

"The initial immunogenicity data sound intriguing," said Dr. Joseph W. Golden, a principal investigator in USAMRIID's virology division. "We look forward to evaluating this vaccine formulation for its potential to protect against SARS-CoV-2 in our mouse models."

The work to be performed by USAMRIID will be financed out of the Company's existing working capital, according to David Goren, Vaxil's Chairman and Chief Executive Officer. The team hopes to secure additional funding for future studies.

"We are pleased to have USAMRIID assess our potential COVID-19 vaccine," said Goren. "The work in the US will support and strengthen the experiments we have already done in Israel in our in-vivo study. Together, the combined research will help the Company plan and execute more efficient pre-clinical and clinical programs."

The Company is not making any express or implied claims that it has completed developing or will be successful in developing a COVID-19 (or SARS-CoV-2) vaccine at this time.

[FooBarAndGrill]

https://finance.yahoo.com/news/vaxil-announces-positive-results-corvax-124000072.html

NOT FOR DISTRIBUTION BY US NEWSWIRE OR IN UNITED STATES

NESS-ZIONA, Israel, Sept. 08, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce that it has achieved positive results for the in vivo (animal) immunogenicity study which commenced on July 14, 2020.

The experiments, performed at the Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Sourasky Medical Center in Israel (the “Tel Aviv Sourasky Medical Centre”) were designed to evaluate, in vivo, the immune response to CorVax™. The results successfully demonstrated both cellular and humoral responses to multiple signal peptides as well as to CorVax™, composed of multiple signal peptides. These results further confirm the potential in the design of Vaxil’s COVID-19 vaccine candidate and provide additional evidence that it generates the anticipated immune response. A total of three injections were inoculated in two mouse strains to better simulate the human immune environment for which CorVax™ was specifically designed. Both mouse strains exhibited a humoral response, developing antibodies as early as 10 days after last injection. Both strains also displayed activated T cells against the signal peptides.

“We are delighted with these results, which indicate that further work is warranted to solidify the evidence behind the success of this study,” said Dr. David Hagin, Director of the Allergy and Clinical Immunology Unit at the Tel Aviv Medical Sourasky Center, and continued “from the outset, I was intrigued by Vaxil’s novel solution to a potential COVID-19 vaccine. We are seeing hundreds of patients at our hospital, daily, and therefore, to be involved in developing a potential solution to a global pandemic is particularly fulfilling.”

“We are very pleased with the outcome of this study, and will now weigh next steps to continue to produce more data, eventually to achieve approval to launch a clinical trial,” said David Goren, Vaxil’s Chairman and Chief Executive Officer, and continued, “our collaboration with Dr. Hagin and his team at the Tel Aviv Sourasky Medical Centre is extremely effective and I thank Dr. Hagin and his team for their outstanding commitment and professionalism.”

The study was performed by a third-party world leading tertiary medical center according to Israeli regulations and the results are expected to be published in the future.

We expect to provide a further update within the next eight weeks.

ABOUT VAXIL

Vaxil is an Israeli immunotherapy biotech company focused on its novel approach to targeting prominent cancer markers and infectious diseases. Its lead product ImMucin™ successfully completed a Phase 1/2 clinical trial in multiple myeloma for which it received orphan drug status from the FDA and EMA. The company aims to continue to develop ImMucin™, a COVID-19 and a tuberculosis vaccine / treatment that has demonstrated promising preliminary results with further preclinical evaluation planned. Additional indications and mAb candidates are under evaluation as immuno-oncology and infectious disease treatments alone and in combination with other treatments.

Vaxil exploits the unique properties of signal peptide domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens. These signal peptide domains are identified by VaxHit™, Vaxil’s proprietary bioinformatic approach. These signal pepdies induce a robust T- and B-cell response across wide and varied HLA subtypes, while acting as true, universal neoantigens. The peptide platform targets these cells by “educating” or specifically activating the immune system to recognize and attack the affected cells. In addition, Vaxil’s mAb platform directly recognizes the target protein expressed on malignant cells and recruits other elements of the immune system to lyse those cells.

The Company is not making any express or implied claims that it has completed developing or will be successful in developing a COVID-19 (or SARS-CoV-2) vaccine at this time.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

[yourfada]

$1 incoming. Doing what MRNA couldn’t.

[Estrella]

$VXLLF @ .0767!

[deadjim]

VXLLF otc vaccine maker -- marked

axil Announces Collaboration Agreement With The Tel Aviv Sourasky Medical Center (Ichilov Hospital), Israel’s Leading Tertiary Care Facility
Not for distribution by US newswire or in United States
NESS-ZIONA, Israel, May 05, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce the signing of a collaboration agreement between the Company and The Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Medical Center (the “Tel Aviv Medical Center”) to advance the Company’s research program to develop a potential peptide vaccine against COVID-19.

This agreement provides Vaxil with vital access to Tel Aviv Medical Center’s research resources including their unique bank of biological samples and its advanced research infrastructure. Dr. David Hagin, Director of the Allergy and Clinical Immunology Unit, will progress our pre-clinical work and clinical trials.

“This collaboration agreement is an central milestone in the pre-clinical stage of our COVID-19 vaccine candidate research, and provides a clear pathway to potential clinical trials during 2020”, said David Goren, Vaxil’s Chairman and Chief Executive Officer. He continued to say “the The Aviv Medical Center is a leading hospital and is at the forefront of fighting the COVID-19 pandemic in Israel. We look forward to working with Dr. Hagin and their world-class medical and research teams on this program.”

Dr. Hagin added “Use of the signal peptide platform, which targets infected cells rather than the virus is unique and exciting. I see great potential in this innovative approach to develop a potential COVID-19 vaccine. We share Vaxil’s vision of creating a vaccine quickly for the benefit of people all over the world.”

The Company does not anticipate the need to raise additional funds to finance this work.

The Company is not making any express or implied claims that it has completed developing or will be successful in developing a vaccine to treat COVID-19 (or SARS-CoV-2) at this time.

[MjMilo]

Not sure what chart you're looking at or what news you're reading but there is nothing compelling about this stock right now...

They are a cancer vaccine research company.

The covid angle was nothing more than a distraction....

The Sourasky collaboration may or may not yield an ything.

I have visited this hospital when I was in israel one year ago.


Right now all trials and most research is not happening on schedule because of Covid...

Vaxil has applied for a patent on the use of peptides in the manufacturing of vaccines. THis technology could also be applied to a Corona vaccine which is not what Vaxil is working on....not the vaccine itself.

Been in and out of this stock for more than one year and a half.

I have communicated with David Goren via email...

I know what the score is here.

[Numbmonk]

Almost time to get back in.

[BruceLake]

News today of a collaboration agreement with the Tel Aviv Sourasky Medical Center. Please note the disclaimer. A lot of companies are getting into deep doodoo with misleading claims regarding Covid-19. They are playing it safe.

NESS-ZIONA, Israel, May 05, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to announce the signing of a collaboration agreement between the Company and The Medical Research, Infrastructure, and Health Services Fund of the Tel Aviv Medical Center (the “Tel Aviv Medical Center”) to advance the Company’s research program to develop a potential peptide vaccine against COVID-19.

https://web.tmxmoney.com/article.php?newsid=5406659349184153&qm_symbol=VXL

[breezy1]

Vaxil-bio.com

[skitahoe]

Thanks, I skimmed it quickly and clearly missed it.

Gary

[Lipkin9393]

Shhh don’t pump it’ll fly on its own

[MOTSUR]

This might have ties to vaxil...who knows
https://112.international/ukraine-top-news/israel-gets-antibodies-to-covid-19-50256.html

[Lipkin9393]

Shhhhh

[MOTSUR]

#17 page 22

[skitahoe]

I don't see us on this list, did I miss it somewhere, or does the company need to do something to call attention to it.

https://milkeninstitute.org/sites/default/files/2020-04/Covid19%20Tracker%20NEW4-3-20-2.pdf

Clearly there is a tremendous amount of work going on for this, I would think if many got together it could be done quicker in a Manhattan Project sort of environment.

Gary

[MOTSUR]

VAXIL COMMENCES PRECLINICAL COVID-19 VACCINE TRIAL AND FILES AN ADDITIONAL COVID-19 PATENT

Posted on March 27, 2020 by David Goren

?

27MAR

Not for distribution by US newswire or in United States
NESS-ZIONA, ISRAEL – March 27, 2020 – VAXIL BIO LTD. (“VAXIL” or the “COMPANY”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to provide an update of its COVID-19 research program and other updates.
COVID-19 VACCINE DEVELOPMENT
In February 2020 we announced that we believed that we had successfully identified a corona virus (COVID-19) vaccine candidate (“VACCINE CANDIDATE”). The Vaccine Candidate is based on unique and patent protected signal peptide technology, utilizing Vaxil’s proprietary VaxHitTM bioinformatics platform. The Vaccine Candidate is also based on successful in vivo experiments testing a tuberculosis signal peptide vaccine.
We are now pleased to announce that we have non-GMP vaccine material in hand and have begun to execute our preclinical program to test the efficacy of our COVID-19 vaccine candidate.
ADDITIONAL PATENT APPLICATION
In early March 2020, we announced our applications for a US patent (U.S 62/987,310) on a coronavirus vaccine intended to provide broad patent protection for novel vaccines, pharmaceutical compositions and methods of treating and preventing infectious disease as well as methods for producing a peptide vaccine against coronaviruses.
We are now also pleased to announce that today, Vaxil has applied for an additional patent in connection with COVID-19. An application for a US patent was filed on March 26, 2020 that is intended to provide coverage for a broader set of vaccine candidates.

[MOTSUR]

"VAXIL CURRENTLY HOLDS 6 FULLY ISSUED PATENTS, WITH AN ADDITIONAL 10 PATENTS PENDING."

[MOTSUR]

https://vaxil-bio.com/universally-applicable/

[MOTSUR]

Thank you. I will be buying a little more tomorrow. $VXLLF

100% BUY RATINGS!!!
https://www.barchart.com/stocks/quotes/VXLLF/opinion

VERY, VERY LITTLE SHORTED VOLUME
http://shortvolumes.com/?t=Vxllf+

https://www.stockscores.com/charts/charts/?ticker=Vxllf

[MjMilo]

The company is Canadian/Israeli...and it trades on the Canadian exchange. They don't acknowledge anything else.
As I have warned everyone before..the US listing is on the greys...THis listing will eventually be retired as the greys is where stox go to die.

If you're going to trade Vaxil you need to be buying on the Canadian side.
Anything else is risky.
There are no market makers and buys and sells are at the discretion of the brokerage houses.
Caveat Emptor.

"Warning! Grey Market securities are not traded on the OTCQX, OTCQB or Pink markets
Broker dealers are not willing or able to publicly quote these securities because of lack of investor interest, company information availability or regulatory compliance."

https://www.otcmarkets.com/stock/VXLLF/profile

[skitahoe]

I don't question the legality of what the company's doing, but I hope that as it grows it will move to get on at least the OTC exchange here in the U.S.

When I first bought through Fidelity I was assured the value of my VXLLF would be equal to VXL.CA, so I haven't worried about it. Of course it's always adjusted to currency fluxuations.

Gary

[BruceLake]

You are correct it trades on the Canadian TSXV Exchange where the market is orderly and legal and where they have filing requirements similar as to what is required by the SEC.

https://web.tmxmoney.com/quote.php?qm_symbol=VXL

Gary, I think MjMilo has pointed out a few times that the company doesn't even recognize that it trades on the greys. BTW when we originally bought in, it was long before Covid-19 and for the longest time it was thinly traded between the 3-5 cent range...that is in CAD = approx .70 USD

[skitahoe]

Any thoughts on the company moving off the grey market. I believe the share price would meet OTC requirements, but I'm unsure if they meet all such requirements. While they probably could go on the Pinks as well, I'm of the belief that it's hardly better than the grey market. The OTC should be the next step, and when the price meets requirements for other exchanges the move to one of those exchanges. By the way, most people think of the Nasdaq, but I believe the AMEX only requires a $1 price is a reasonable step up that could be achieved far quicker with no consideration of a reverse split which I would hate to see.

In reality, if our vaccine truly proved effective for coronavirus, and was in some way determined superior to others in development, a price in excess of $4 could come quickly as well. I suspect such a determination would result in either a partnership for it's development, or a buyout of either the entire company, or the product.

I certainly agree with all who find that getting information about the company is rather like pulling teeth, but many biotechs are no different. The grey market might limit it a little more, but the fact that it's listed in Canada should provide roughly the same information as what's required by our SEC.

Gary

Gary

[Elcappy1]

Looks like it...

[Jim Beem]

What is this trading on? No bid and ask showing

[Jim Beem]

This trading in Grey's?

[apr1]

Why is the bid and the ask not shown on this ticker symbol?

[Gumby007]

New investor presentation featuring covid 19 vaccines
https://vaxil-bio.com/wp-content/uploads/2016/07/Vaxil-Overview-Exec-Sum-public-v4-2.pdf

[Gumby007]

https://nationalpost.com/pmn/health-pmn/israel-tests-coronavirus-vaccine-prototype-on-rodents-at-defense-lab

[BDEZ]

Barchart posts strong buy for VXLLF.

https://www.barchart.com/stocks/quotes/VXLLF/overview

[BDEZ]

Thanks Bruce!...VXLLF.

[BDEZ]

This is great news thanks Camp, nice uptick today for VXLLF and hope it continues.

[Campeese]

Huge news! $VXLLF VAXIL COMMENCES PRECLINICAL COVID-19 VACCINE TRIAL AND FILES AN ADDITIONAL COVID-19 PATENT @nasdaq/vaxil-commences-preclinical-covid-19-vaccine-trial $VXLLF #news/biotech #news/healthcare #Covid-19 #coronavirus

[BruceLake]

Some exciting news. I do not have a direct link. This is from the Toronto Stock Exchange.

https://web.tmxmoney.com/article.php?newsid=8915833043322250&qm_symbol=VXL

VAXIL COMMENCES PRECLINICAL COVID-19 VACCINE TRIAL AND FILES AN ADDITIONAL COVID-19 PATENT

Not for distribution by US newswire or in United States

NESS-ZIONA, Israel, March 27, 2020 (GLOBE NEWSWIRE) -- VAXIL BIO LTD. (“Vaxil” or the “Company”) (TSX VENTURE: VXL), an innovative immunotherapy biotech company specializing in cancer and infectious diseases, is pleased to provide a update of its COVID-19 research program and other updates.

COVID-19 Vaccine Development

In February 2020 we announced that we believed that we had successfully identified a corona virus (COVID-19) vaccine candidate (“Vaccine Candidate”). The Vaccine Candidate is based on unique and patent protected signal peptide technology, utilizing Vaxil’s proprietary VaxHit™ bioinformatics platform. The Vaccine Candidate is also based on successful in vivo experiments testing a tuberculosis signal peptide vaccine.

We are now pleased to announce that we have non-GMP vaccine material in hand and have begun to execute our preclinical program to test the efficacy of our COVID-19 vaccine candidate.

Additional Patent Application

In early March 2020, we announced our applications for a US patent (U.S 62/987,310) on a coronavirus vaccine intended to provide broad patent protection for novel vaccines, pharmaceutical compositions and methods of treating and preventing infectious disease as well as methods for producing a peptide vaccine against coronaviruses.

We are now also pleased to announce that today, Vaxil has applied for an additional patent in connection with COVID-19. An application for a US patent was filed on March 26, 2020 that is intended to provide coverage for a broader set of vaccine candidates.

Exercise of Warrants

The Company also wishes to announces that to date, we have received aggregate proceeds of $1,047,000 from the exercise of previously issued (January 2018) warrants, having an exercise price of $0.10 per warrant. These funds will be applied to advancing the Company’s research program.

“This is a very exciting moment for us, as we begin our lab work, less than six weeks from the first discovery. We are pleased with the progress that we have made to date on the development of our potential COVID-19 vaccine,” said David Goren, Vaxil’s Chairman and Chief Executive Officer, and continued, “During the following weeks, we will work to advance our preclinical research for the development of this much needed vaccine and we look forward to sharing additional information as we progress through our research program.”

[skitahoe]

Milo, you could be very right, but what if they have something the really big players in the industry want. That could be a big game changer for a tiny company like this. I believe anything is possible until it's determined that they have one or more vaccines they're ready to mass produce and get out to the population.

I'm no fan of Trump, but I wouldn't be surprised if a vaccine were rushed into production so this Fall we can get it, roughly in 8 months rather than the year to 18 months experts like Dr. Fauci indicated. I don't suspect that it will be as thoroughly tested as people like Dr. Fauci would prefer, but it will be out, and hopefully it will work.

Sadly, we just overtook Italy in terms of numbers infected, and shortly we'll overtake China, not in deaths, but in people confirmed to be infected. Clearly we need to take more stringent measures, not ease up as the President would like to do.

Gary

[MjMilo]

Vaxil is a small bit player out of the Weizmann institute in Rehovot Israel...it highly unlikely as I said several weeks ago that they will play any part in the vaccine development...There are a dozen other companies that are light years ahead and a vaccine is already being tested in human trials...At best this was a peripheral play for Covid..

Their strength is in their cancer vaccine/research.

None of you even knew about this company before Covid...not one of you was here.

[breezy1]

So this indicates Astrozenica would need to consult with Vaxil

Correct?

[Gumby007]

That’s a pretty telling article. Monoclonal antibodies, David Goren ties.
Do we do “ monoclonal antibody “?? Yes we do from our patent under Classificstions. First one ... “ C07K16/28 Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
View 4 more classifications”

[Gumby007]

Here's an important article (March 21, 2020): https://www.thisismoney.co.uk/money/markets/article-8138573/Drugs-giant-AstraZeneca-talks-governments-cure-virus.html

[BDEZ]

Thanks Gumby, great stuff.

VXLLF

[Gumby007]

Magnifier Research has offered a new research report titled Global Dendritic Cell Cancer Vaccines Market Size, Status and Forecast 2019-2025 Report just released mentions vxl “ The report speaks about the summary of the market competitive spectrum: 3M Company, Activarti, Argos Therapeutics, Batavia Bioservices, Bellicum Pharmaceuticals, Creagene, DanDrit Biotech, DCPrime, Sanpower Corporation, Elios Therapeutics, ImmunoCellular Therapeutics, Immunicum, Kiromic, Medigene, Merck, Northwest Biotherapeutics, Glaxo Smith Kline, Tellaorporation, Vaxil BioTherapeutics,” https://nysenewstimes.com/global-dendritic-cell-cancer-vaccines-market-growth-analysis-2019-2025-3m-company-activarti-argos-therapeutics/

[Gumby007]

The drugs is MTBuVax good for malaria and made by Vaxil
https://www.google.com/amp/s/www.cnbc.com/amp/2020/03/19/coronavirus-treatment-trump-directs-fda-to-examine-whether-malaria-drug-can-be-used.html

The drugs is MTBuVax good for malaria and made by Vaxil

https://patents.google.com/patent/US20120177677A1/en

"the Malaria P. Falciparum antigens—Circumsporozoit protein precursor, Malaria exported protein-1, Liver stage"

MTBuVax
https://finder.startupnationcentral.org/m/company_page/vaxil-biotherapeutics

"VaxHit technology for anti-infective indications and isolated MTBuVax"

[breezy1]

Uhh yes it would be perfect timing considering our planet’s situation

[BDEZ]

Still a very Strong buy here for VXLLF.

https://www.barchart.com/stocks/quotes/VXLLF/overview

[breezy1]

I think ?? it’s in the cards

[BDEZ]

Yeah didn't realize how recent that run was, man that would be so cool here with VXLLF.

[breezy1]

This reminds me of GNPX when it was .24 and went to 6 in three months. Phase 1/2